This is a $35,943,677.00 definitive cost-type contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Amgen Inc., a for-profit manufacturer, on September 26, 2019. The contract is to advance the development of romiplostim for treatment of hematopoietic subsyndrome-acute radiation syndrome (HS-ARS) and chemotherapy-induced thrombocytopenia (CIT), as well as a drug delivery device feasibility project, with a completion date of September 10, 2025. The contract was not set aside and originated from a Broad Agency Announcement posted by the Biomedical Advanced Research and Development Authority (BARDA) seeking proposals for advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats.
Generated 5/2/24, 9:58 AM